Clinical Trial Update: Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating toripalimab with pemetrexed and anlotinib in T790M-positive non-small cell lung cancer after osimertinib resistance.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Pemetrexed (pemetrexed)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Guangzhou Institute of Respiratory Disease | Conditions: IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy | Phase 2 | Status: UNKNOWN